Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
100%(5 trials)

Phase Distribution

Ph phase_3
3
50%
Ph phase_2
3
50%

Phase Distribution

0

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(5)

Detailed Status

Completed5
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (50.0%)
Phase 33 (50.0%)

Trials by Status

completed583%
not_yet_recruiting117%

Recent Activity

0 active trials
Showing 5 of 6
not_yet_recruitingphase_2

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

NCT07213960
completedphase_2

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

NCT03453619
completedphase_2

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

NCT03226678
completedphase_3

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

NCT03525613
completedphase_3

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

NCT03525600
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07213960Phase 2

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

Not Yet Recruiting
NCT03453619Phase 2

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Completed
NCT03226678Phase 2

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Completed
NCT03525613Phase 3

A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Completed
NCT03525600Phase 3

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Completed
NCT04085601Phase 3

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6